AstraZeneca’s in Vivo CAR-T Led to Early Responses, but One Death in China Trial

Why It Matters

The data signal a potential faster, cheaper CAR‑T option for a high‑need cancer, but safety risks could delay regulatory approval and market adoption.

Key Takeaways

• In vivo CAR‑T shows early activity in multiple myeloma
• Trial enrolled 30 Chinese patients, 33% achieved partial response
• One patient died from severe cytokine release syndrome
• Safety profile remains uncertain, prompting cautious regulatory review
• AstraZeneca aims to commercialize therapy by 2028

Pulse Analysis

AstraZeneca’s entry into cell therapy accelerated last year when it acquired an in‑vivo CAR‑T platform from a biotech partner. Unlike traditional ex‑vivo approaches that require extracting a patient’s T cells, engineering them in the body, the in‑vivo method promises faster manufacturing, lower costs, and broader accessibility. The technology targets B‑cell maturation antigen (BCMA) on malignant plasma cells, a proven vulnerability in multiple myeloma. By integrating the platform into its oncology portfolio, AstraZeneca seeks to compete with established CAR‑T players such as Novartis and Bristol‑Myers Squibb, while diversifying its revenue streams beyond small‑molecule drugs.

The first‑in‑human study, conducted at three sites in China, enrolled 30 patients with relapsed or refractory multiple myeloma. Early data released this week show an overall response rate of roughly 33%, including several partial remissions within two months of dosing. However, the trial also recorded a fatal event attributed to severe cytokine release syndrome, underscoring the safety challenges of systemic CAR‑T activation. Chinese regulators have welcomed the innovative approach but emphasized rigorous monitoring, while investors are weighing the promise of rapid‑manufacture against the risk of adverse outcomes.

Looking ahead, AstraZeneca plans to expand the program into a pivotal Phase III trial across Europe and the United States, targeting a 2028 market launch if efficacy and safety benchmarks are met. The company’s sizable cash reserves and partnership network could accelerate scale‑up, positioning the in‑vivo CAR‑T as a cost‑effective alternative to current autologous products priced above $400,000 per treatment in the U.S. Success would not only reshape the multiple myeloma landscape but also validate a broader shift toward in‑situ gene‑editing therapies across oncology.